BioScrip (NASDAQ:BIOS) announced its earnings results on Friday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.11), Briefing.com reports. The firm had revenue of $183.57 million during the quarter, compared to analysts’ expectations of $188.39 million. During the same quarter last year, the business earned ($0.03) EPS. BioScrip’s quarterly revenue was up .5% on a year-over-year basis.
BIOS stock traded down $1.08 during trading on Friday, hitting $2.42. 7,554,369 shares of the company’s stock were exchanged, compared to its average volume of 630,699. The stock has a market cap of $458.38 million, a price-to-earnings ratio of -5.49 and a beta of 0.76. BioScrip has a 52-week low of $2.31 and a 52-week high of $4.14.
Hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its stake in shares of BioScrip by 8.5% in the second quarter. Bank of America Corp DE now owns 243,794 shares of the company’s stock valued at $714,000 after buying an additional 19,096 shares in the last quarter. Northern Trust Corp increased its stake in BioScrip by 10.5% during the second quarter. Northern Trust Corp now owns 1,434,116 shares of the company’s stock worth $4,202,000 after acquiring an additional 136,809 shares during the last quarter. Engineers Gate Manager LP acquired a new stake in BioScrip during the third quarter worth about $146,000. BlackRock Inc. increased its stake in BioScrip by 0.4% during the third quarter. BlackRock Inc. now owns 7,616,244 shares of the company’s stock worth $23,610,000 after acquiring an additional 31,899 shares during the last quarter. Finally, Rothschild & Co. Asset Management US Inc. increased its stake in BioScrip by 82.8% during the third quarter. Rothschild & Co. Asset Management US Inc. now owns 2,174,826 shares of the company’s stock worth $6,742,000 after acquiring an additional 985,235 shares during the last quarter. Hedge funds and other institutional investors own 82.61% of the company’s stock.
A number of brokerages have recently issued reports on BIOS. Zacks Investment Research lowered BioScrip from a “hold” rating to a “sell” rating in a research report on Thursday, January 3rd. BidaskClub lowered BioScrip from a “sell” rating to a “strong sell” rating in a research report on Wednesday, March 6th. TheStreet upgraded BioScrip from a “d+” rating to a “c-” rating in a research report on Monday, November 26th. Canaccord Genuity began coverage on BioScrip in a research report on Wednesday, December 12th. They set a “buy” rating and a $5.00 target price on the stock. Finally, Lake Street Capital increased their target price on BioScrip from $4.50 to $10.00 and gave the company a “buy” rating in a research report on Friday, December 7th. Two analysts have rated the stock with a sell rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $5.63.
TRADEMARK VIOLATION WARNING: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2019/03/15/bioscrip-bios-posts-earnings-results-misses-estimates-by-0-11-eps.html.
BioScrip Company Profile
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
See Also: Are all No-Load Funds Equal?
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.